Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia–Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability
Authors' conclusion
We found that oral dantrolene produced no serious adverse effects within the reported dose range, and was well tolerated by most MH-susceptible patients presenting myopathic symptoms.
Study context
- Population
- Malignant hyperthermia (MH)-susceptible patients (positive caffeine-halothane contracture test (CHCT)) with myopathic manifestations (myalgia, fatigue, rhabdomyolysis), 1994–2018started oral dantrolene
- Participants
- 164 patients
- Outcome
- Occurrence of serious adverse effects and adherence to oral dantrolene therapy
Methodological detailsdatabase review
- Database review
Main finding
As reported in the abstract
Serious adverse effects
- No serious adverse effects reported
Observational data: associations, not effects.
Further findings
Response to dantrolene with RYR1 variant
| OR (95% CI) | P value | ||
|---|---|---|---|
| RYR1 variant | 6.4 (1.3–30.9) | P = 0.013 | |
| 0.050.21520Odds ratio (log scale) |
| Outcome | Values | Estimate | P value |
|---|---|---|---|
| Responders: MH history vs clinical myopathy with nonpertinent anesthetic history (subgroup) | MH history 97% · Clinical myopathy 79% | (95% CI 8.5–28) | P < 0.001 |
| Dantrolene dose | Responders median 50 (range 25–400) mg·day −1 · Nonresponders median 200 (range 25–400) mg·day −1 |
Safety
Discontinuation of treatment
- Discontinued due to adverse effects
- 16
- Discontinued due to lack of improvement
- 6
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia–Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability. Anesth Analg. Published 6 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →